ImmunityBio (IBRX) Non-Current Assets (2014 - 2026)
ImmunityBio (IBRX) reported Non-Current Assets of $193.7 million for Q1 2026, little changed year-over-year from $194.6 million in Q1 2025, and up 3.56% on a QoQ basis from $187.0 million in Q4 2025.
ImmunityBio (IBRX) has 13 years of Non-Current Assets data on file, last reported at $193.7 million in Q1 2026.
- Quarterly Non-Current Assets changed 0.47% year-over-year to $193.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $764.1 million (down 3.99% YoY) and the FY2025 annual result came in at $187.0 million, down 5.71% from the prior year.
- Non-Current Assets climbed to $193.7 million in Q1 2026 per IBRX's latest filing, from $187.0 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $229.9 million in Q1 2023 and bottomed at $177.2 million in Q1 2022.
- The 5-year median for Non-Current Assets is $201.5 million (2024), against an average of $203.4 million.
- The widest annual swing landed in 2022, when Non-Current Assets surged 74.92%; it then retreated 10.85% in 2024.
- Tracing IBRX's Non-Current Assets over 5 years: stood at $221.8 million in 2022, then fell by 5.15% to $210.4 million in 2023, then decreased by 5.71% to $198.3 million in 2024, then decreased by 5.71% to $187.0 million in 2025, then rose by 3.56% to $193.7 million in 2026.
- Per Business Quant, the three latest IBRX Non-Current Assets figures stand at $193.7 million (Q1 2026), $187.0 million (Q4 2025), and $189.5 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 4.56 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 62,953.78 |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 486.60 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 5.83 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 30.30 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 14.75 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 22.66 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 910.24 Mn |
| 10 | ImmunityBio | 7.72 Bn | 7.34 Bn | 43.97 Mn | 193.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 193.68 Mn |
| Dec 31, 2025 | 187.02 Mn |
| Sep 30, 2025 | 189.49 Mn |
| Jun 30, 2025 | 193.94 Mn |
| Mar 31, 2025 | 194.60 Mn |
| Dec 31, 2024 | 198.35 Mn |
| Sep 30, 2024 | 201.42 Mn |
| Jun 30, 2024 | 201.50 Mn |
| Mar 31, 2024 | 204.96 Mn |
| Dec 31, 2023 | 210.37 Mn |
| Sep 30, 2023 | 217.34 Mn |
| Jun 30, 2023 | 224.40 Mn |
| Mar 31, 2023 | 229.91 Mn |
| Dec 31, 2022 | 221.78 Mn |
| Sep 30, 2022 | 209.85 Mn |
| Jun 30, 2022 | 202.73 Mn |
| Mar 31, 2022 | 177.25 Mn |
| Dec 31, 2021 | 134.56 Mn |
| Sep 30, 2021 | 119.97 Mn |
| Jun 30, 2021 | 132.57 Mn |
| Mar 31, 2021 | 109.86 Mn |
| Dec 31, 2020 | 109.67 Mn |
| Sep 30, 2020 | 82.52 Mn |
| Jun 30, 2020 | 80.88 Mn |
| Mar 31, 2020 | 82.90 Mn |
| Dec 31, 2019 | 87.37 Mn |
| Sep 30, 2019 | 88.59 Mn |
| Jun 30, 2019 | 88.65 Mn |
| Mar 31, 2019 | 94.83 Mn |
| Dec 31, 2018 | 93.18 Mn |
| Sep 30, 2018 | 101.07 Mn |
| Jun 30, 2018 | 101.34 Mn |
| Mar 31, 2018 | 103.04 Mn |
| Dec 31, 2017 | 117.98 Mn |
| Sep 30, 2017 | 120.88 Mn |
| Jun 30, 2017 | 120.06 Mn |
| Mar 31, 2017 | 107.73 Mn |
| Dec 31, 2016 | 112.35 Mn |
| Sep 30, 2016 | 117.94 Mn |
| Jun 30, 2016 | 124.98 Mn |
| Mar 31, 2016 | 131.89 Mn |
| Dec 31, 2015 | 69.31 Mn |
| Sep 30, 2015 | 12.68 Mn |
| Jun 30, 2015 | 132.64 Mn |
| Dec 31, 2014 | 623,000.00 |